A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-03-02
Adverse events
Grade 1 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-05-09 (study day 53); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-12-20 (study day 278); relationship: not assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-12-23 (study day 281); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-03-29 (study day 378); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-08-03 (study day 505); relationship: N
Data queries
No data queries.